We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Circassia Group plc (CIR) Ordinary Shares 0.08p

Sell:36.50p Buy:37.90p 0 Change: 0.50p (1.34%)
Market closed Prices as at close on 24 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:36.50p
Buy:37.90p
Change: 0.50p (1.34%)
Market closed Prices as at close on 24 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:36.50p
Buy:37.90p
Change: 0.50p (1.34%)
Market closed Prices as at close on 24 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Circassia settles LungFit dispute with Beyond Air

    26 May 2021 12:14

    (Sharecast News) - Respiratory diagnostics-focussed medical device company Circassia Group has signed an agreement to settle its contractual dispute with Beyond Air, it announced on Wednesday, around the...

  • Circassia shares rise as it flags 'significant' revenue growth

    9 January 2020 12:03

    (Sharecast News) - Respiratory disease-focussed pharmaceutical company Circassia Pharmaceuticals updated the market on its trading for the year ended 31 December on Thursday, announcing that it expected...

  • Adams increases stake in Circassia

    3 January 2020 14:41

    (Sharecast News) - Adams announced on Friday that, on 2 January, it purchased an additional 2,400,000 ordinary shares in Circassia on the AIM market, at an average price of 19p per share, for a total cash...

  • Circassia shares plunge as its partner terminates agreement

    19 December 2019 16:44

    (Sharecast News) - Specialty biopharmaceutical company Circassia Pharmaceuticals updated the market on its licensing agreement with BeyondAir, previously AIT Therapeutics, on Thursday.

  • Circassia appoints Jonathan Emms to new COO role

    12 August 2019 15:49

    (Sharecast News) - Specialty biopharmaceuticals company Circassia Pharmaceuticals announced the appointment of Jonathan Emms to the newly-created role of chief operating officer on Monday.

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2022. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.